

Development of a multi-specific target fusion protein for autoimmune disease



IMMUNOLOGY	Candidate
Product Type	Tri-specific Fc-fusion TRAP protein
Indication	Psoriasis, with extended indications for Rheumatoid Arthritis (RA) and Hidradenitis Suppurativa (HS)
Target	IL-17A, IL-17F and TNFa
MoA (Mechanism of Action)	Dual blockade therapy targeting: 1. IL-17A and IL-17F to induce IL-23-mediated pro-inflammatory T helper 17 (Th17) response 2. TNFa for IL-12-mediated Th1 response Activates a synergistic cytokine response while lowering the risk of anti-drug antibody response.
Competitiveness	<ul style="list-style-type: none"> - Effective inflammation control by targeting both innate and adaptive immune responses - High affinity and potent neutralization ability - Increased protein stability and flexibility by linker design - Fc-engineering to extend protein half-life - Improved safety and low anti-drug antibody response - Ease of administration through subcutaneous formulation - Reduced financial burden via multi-target approach
Development Stage	Candidate
Route of Administration	Subcutaneous administration